Spyre Therapeutics expects six trial readouts in 2026
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2
January 12, 2026 8:01 AM EST6 in 26 expected proof-of-concept (POC) readouts across SKYLINE and SKYWAY trials
SKYLINE platform trial in ulcerative colitis (UC) recruiting faster than expected with SPY001 enrollment complete ahead of schedule; Part A readouts accelerated, now expected to start in Q2
SKYWAY basket trial enrollment on track across rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA); All readouts expected in 4Q 2026
Kate Tansey Chevlen appointed Chief Commercial Officer (CCO)
Strong balance sheet with pro forma cash, cash equivalents, and marketable securities balance of... More
